Company also announces publication of the PROACTIVE-HF trial design rationale, the first global IDE trial for PA pressure-guided heart failure management, in the Journal of Cardiac Failure

LISLE, Ill. , Sept. 30, 2022 /PRNewswire/ -- Endotronix, Inc., a privately-held digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced implantation of the 400th Cordellaâ„¢ Pulmonary Artery (PA) Pressure Sensor. The milestone includes successful implants across the company's completed European trials, SIRONA First-in-Human and SIRONA 2, as well as the currently enrolling global investigational device exemption (IDE) trial, PROACTIVE-HF. Designed to unlock the power of comprehensive HF management, PROACTIVE-HF is evaluating a multisystem care delivery model that includes daily PA pressure and vital sign measurements as well as self-reported symptoms to optimize remote care.

Additionally, the PROACTIVE-HF trial design manuscript was published today in the Journal of Cardiac Failure. The peer-reviewed publication provides the rationale of the trial design, explains the recent switch to a single arm study and describes key advantages of the Cordella Heart Failure System and Sensor relative to commercially available solutions. Lead author and National Principal Investigator of the PROACTIVE-HF trial, Dr. Liviu Klein shared, "The heart failure community is embracing the benefits of PA pressure-guided management. The comprehensive Cordella System and Sensor builds on previous evidence and advances our ability as clinicians to provide guideline directed medical therapy (GDMT) to improve patient outcomes. We are proud to be part of this journey of demonstrating sustained positive patient outcomes through PROACTIVE-HF." Dr. Klein also serves as Section Chief, Advanced Heart Failure, Mechanical Circulatory Support, Pulmonary Hypertension and Heart Transplant at the University of California San Francisco .

"As we push towards full enrollment in the study, the momentum and energy from our phenomenal clinical partners is fantastic," stated Harry Rowland , CEO of Endotronix. "This recent publication expands our clinical foundation. The Cordella System and Sensor, together, provide a meaningful advancement in heart failure management that we believe will help clinicians achieve better patient engagement and outcomes."

Providing a more comprehensive approach to patient management, the Cordella Heart Failure System is designed to enable scalable remote heart failure management that combines patient engagement, GDMT uptitration, and diuretic optimization to improve care and prevent worsening heart failure. The platform consists of a patient management system that securely collects daily vital sign measurements and self-reported symptoms, coupled with a seamlessly integrated, next-generation implantable PA pressure sensor, which provides PA pressure data. Combined, this trended information is accessed through a best-in-class clinician portal to inform decisions of when to proactively titrate medications and improve patient care between office visits, all while supporting reimbursement for care delivery activities.

PROACTIVE-HF is the first global IDE clinical trial for PA pressure-guided heart failure management. Due to complete enrollment in early 2023, PROACTIVE-HF will support U.S. regulatory approval and market access of the sensor. The single-arm study will enroll 450 New York Heart Association (NYHA) class III heart failure patients at approximately 100 sites worldwide and will assess the safety and efficacy of the Cordella Sensor. Recently published positive clinical results from SIRONA 2, the CE Mark clinical trial, demonstrated safe and effective comprehensive HF management with low HF hospitalization rates, improved patient functional status as measured by NYHA classification, consistently high patient compliance with daily measurements, and an overwhelming patient preference for seated PA pressure readings instead of lying flat.

These achievements follow a recent round of financing by the company that secured funding through pre-market approval (PMA) of the sensor.

Endotronix, Inc., a medical technology company, delivers an integrated platform that provides comprehensive, reimbursable health management innovations for patients suffering from advanced heart failure. Their solution, the Cordellaâ„¢ Heart Failure System, includes a cloud-based disease management data system and at home hemodynamic management with a breakthrough implantable wireless pulmonary artery pressure sensor for early detection of worsening heart failure. Learn more at www.endotronix.com.

The Cordella System, without the sensor, is available for commercial use in the U.S. and E.U. and is currently in cardiology centers across the U.S. The Cordella Sensor is currently under clinical investigation and is not currently available for commercial use in any geography.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain predictions, estimates or other information that might be considered forward-looking statements. Such forward-looking statements are not a guarantee of future performance.

MEDIA CONTACT: Carla Benigni SPRIG Consulting, LLC +1 (847) 951-7430 carla@sprigconsulting.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/endotronix-celebrates-400th-implant-of-cordella-pulmonary-artery-pressure-sensor-for-proactive-remote-heart-failure-management-301638054.html

We’re in a volatile bear market right now, and key riddle investors need to answer is, which stocks are going to bring the best returns, even in today’s uncertain conditions. One market segment that can’t be ignored is the low-cost penny stocks. These equities, typically priced under $5 per share, offer the best combination of risk and reward: a minimal cost of entry, and frequently triple-digit upside potential. Going beyond the argument that you get more for your money, even minor price apprec

Alzheimer's therapies are big news lately. The disease is the leading cause of dementia and memory loss. The Alzheimer's Association estimates that 6.5 million Americans 65 and older are living with Alzheimer's dementia (AD) and by 2050, the number of people 65 and older with AD is projected to reach 12.7 million.

Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.

The WHO found that omicron subvariant XBB, which may be even more resistant to antibodies than other variants, spread to more countries in the week ending Oct. 16 from the previous week.

Photo Illustration by The Daily Beast / GettyWe’re all going to die eventually—but what if you knew when you’d be at risk for dropping dead, based solely on the way you walk? A new study shows that measurements taken with wrist-worn motion sensors can be used to predict one’s mortality risk up to five years later. As one of the largest validations of wearable technology to date, the research raises the possibility of one day using the motion detection system in smartphones to survey patient heal

Early this month, the World Health Organization’s director said that ingredients in four cold and cough syrups made in India may have been linked to acute kidney injuries and the deaths of 66 children in Gambia — and that the products may have been distributed to other countries. Days later, authorities in India began an investigation and halted all production by the company that made the tainted medication. This week, authorities in Indonesia banned the sale of all cough syrups nationwide. They

Four people linked to viral video footage of Mississippi day care employees using a scary mask to frighten young children are facing charges of felony child abuse, and a fifth person faces two misdemeanor counts, authorities say. The daycare’s owner, Sheila Sanders, is not facing charges.

Picking the right markets to compete in makes surviving bear markets much more manageable for these companies.

Biotech company Novavax (NASDAQ: NVAX) has had a terrible year on the stock market, with its shares down by 86% year to date. The company does still face some challenges. The coronavirus vaccine market, where it plans to make its money for the next few years, could shrink substantially starting next year.

Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.

Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

The U.S. is seeing an alarming surge in respiratory viruses like RSV among kids. One hospital is so slammed its considering asking the national guard for help.

Chrissy Teigen is expecting another baby, and she just shared some pics of her toned legs in heels and a minidress on Instagram. Chrissy loves yoga and Pilates.

HCA Healthcare, Acadia Healthcare, Universal Health Services and Tenet Healthcare have been highlighted in this Industry Outlook article.

Sathya Elumalai was finding it hard to manage his mother's health after she was diagnosed with four chronic conditions. Rather than guess her health status for the day, he decided to co-found Aidar Health to get that information directly and reliably. In founding Aidar, Elumalai also created and launched MouthLab, a device it claims tracks 10 key health parameters in under a minute.

Some epidemiologists are predicting a rise in cases of COVID starting soon with Halloween & winter setting in. We share latest on why and what to do.

Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.

Canada is expected to see a spike in influenza cases this coming season. Here's what you need to know.

When it comes to healthcare spending, 'consumers can only really choose between paying up or walking away,' one analyst told MarketWatch.

Komodo dragons are the largest lizard in the world, growing to 3m in length (10 feet) and weighing up to 70kg (150lbs). They are powerful animals and capable hunters, possessing strong jaws, ferocious claws, and surprising strength and speed. Although these dragons are rumoured to kill their prey with toxic saliva, the truth is that they attack with the intent to kill immediately. They do track prey if it escapes, but this is not their preferred means of hunting. Occasionally, animals die of blood loss or fatigue after injury and the Komodo dragon's keen sense allows it to track prey at a great distance. This contributes to the success of hunting following an attack, as well as to the myth of prey death due to sepsis. A recent discovery on 2005 showed that the dragons do have mild venom which interferes with blood clotting. This would cause prey to die after otherwise non-lethal injuries. MRI examinations of Komodo dragons showed venom glands in the lower jaws of the animals. Toxic proteins in the glands not only inhibit blood clotting, but they also reduce blood pressure and cause muscle paralysis. Prey will suffer from hypothermia and shock as the result of a venomous bite. Komodo dragons are fiercely competitive when it comes to mating rights, battling other males and pinning them to the ground. Even the female will fight to resist mating and the male struggles to restrain her to allow for successful intercourse. Mating pairs are often monogamous, which is very rare among lizards. This Komodo dragon was observed wandering the woodlands of Komodo Island in Indonesia, one of the few islands in the world where these incredible lizards reside. This is a wild dragon that was resting under branches as he made his way through the forest. To witness a Komodo dragon in the wild is a rare and wonderful experience.